



MONTHLY PROGRESS REPORT

Name of CSE Issuer: LeenLife Pharma International Inc. (the "Issuer").

Trading Symbol: LLP

Number of Outstanding Listed Securities: 34,315,318

Date: Month of October 2017

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company has developed a proprietary process to manufacture omega-3 fatty acids from flax seeds. The Issuer plans to bring its proprietary omega fatty acid products to Canada and the United States. The Issuer has developed technology to combine omega fatty acids into various food products such as bread, cheese, noodles, milk, juices and chocolate.

2. Provide a general overview and discussion of the activities of management.

Our technology

The Company is currently customizing the technology for entry into the markets of Canada and the United States. This will provide the Company with proprietary technology and lower the cost of production. The Company has been focused on Poland and is preparing for entry to Canada and the United States. According to various marketing reports 50% of future world sales of omega products will be in North America, and 25% in Europe.

On October 17, 2017 the Company announced it had entered into an exclusive agreement with BioCube Corporation Ltd. ("BioCube"), an Australian company with offices in British Columbia, to purchase equipment to manufacture the Company's Omega 3 products based on flax seed oil.

BioCube, offers LeenLife Pharma an on or off-grid platform that provides seamless integration into the commercial production process of LeenLife Pharma's proprietary and industry leading Omega-3 formulations.

BioCube has developed a proprietary processing plant, having intellectual property including patents, patent applications and proprietary information and technical information (the "BioCube Processor"). The Company has identified a use for the BioCube Processor along with proprietary technology of its own to process flaxseed oil to produce its Omega 3 products. BioCube has agreed to manufacture the BioCube Processor for flaxseed oil exclusively for the Company on following terms, subject to approval by the Canadian Securities Exchange:

1. **Advance payment of fixed fee to BioCube as an annual minimum royalty to be applied against a royalty of 2% of net sales of products produced using the BioCube Processor. The Company has the option to purchase one-half of the royalty for consideration of one million dollars.**
2. **Issuance of one million shares of the Company's stock to BioCube of which 50% will vest after one year and 50% will vest after two years.**
3. **The term of the agreement is 5 years with renewals of 5-year periods.**

The Company is totally satisfied that the efficiency of the BioCube and the BioCube process will address concerns of food grade quality control, cost, production quotas and handling. The Company has decided to set up manufacturing facilities in the Greater Vancouver area. After a careful analysis of costs and market confidence, it was determined that the first manufacturing center should be close to the core of Company operations.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable (other than as disclosed in Section 2 above).

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable (other than as disclosed in Section 2 above).

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Not applicable

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Company's primary source of funding is through the issuance of share capital. When the capital markets are depressed, the Company's activity level normally declines accordingly. As capital markets strengthen and the Company is able to secure equity financing with favorable terms, the Company's activity levels and the size and scope of planned projects will typically increase.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 7, 2017.

Casey Forward

Name of Director or Senior Officer

/s/ Casey Forward

Signature

Director

Official Capacity

Issuer Details <i>Name of Issuer</i> LeenLife Pharma International Inc.	<i>For Month End</i> October 2017	<i>Date of Report</i> <i>YY/MM/DD</i> 17/11/07
<i>Issuer Address</i> Suite 380 – 580 Hornby Street		
<i>City/Province/Postal Code</i> Vancouver, BC, V6C 3B6	<i>Issuer Fax No.</i>	<i>Issuer Telephone No.</i> (778) 688-1799
<i>Contact Name</i> Casey Forward	<i>Contact Position</i> Director	<i>Contact Telephone No.</i> (778) 688-1799
<i>Contact Email Address</i> casey@caseyforward.com	<i>Web Site Address</i> www.leenlifepharma.com	